These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 24300852)

  • 1. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
    Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
    Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
    Harrington KH; Gudgeon CJ; Laszlo GS; Newhall KJ; Sinclair AM; Frankel SR; Kischel R; Chen G; Walter RB
    PLoS One; 2015; 10(8):e0135945. PubMed ID: 26305211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
    Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
    Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
    Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
    Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Lichtenegger FS; Köhnke T; Vick B; Jeremias I; Metzeler KH; Altmann T; Schneider S; Fiegl M; Spiekermann K; Bauerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Leukemia; 2016 Feb; 30(2):484-91. PubMed ID: 26239198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.
    Arndt C; von Bonin M; Cartellieri M; Feldmann A; Koristka S; Michalk I; Stamova S; Bornhäuser M; Schmitz M; Ehninger G; Bachmann M
    Leukemia; 2013 Apr; 27(4):964-7. PubMed ID: 23325142
    [No Abstract]   [Full Text] [Related]  

  • 10. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.
    Aliperta R; Cartellieri M; Feldmann A; Arndt C; Koristka S; Michalk I; von Bonin M; Ehninger A; Bachmann J; Ehninger G; Bornhäuser M; Bachmann MP
    Blood Cancer J; 2015 Sep; 5(9):e348. PubMed ID: 26383821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells.
    Yan Z; Gu R; Ma H; Chen N; Zhang T; Xu Y; Qiu S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Cell Oncol (Dordr); 2024 Oct; 47(5):1879-1895. PubMed ID: 39008193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
    Zugmaier G; Klinger M; Schmidt M; Subklewe M
    Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
    Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
    Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
    Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
    Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
    Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
    Ravandi F; Subklewe M; Walter RB; Vachhani P; Ossenkoppele G; Buecklein V; Döhner H; Jongen-Lavrencic M; Baldus CD; Fransecky L; Pardee TS; Kantarjian H; Yen PK; Mukundan L; Panwar B; Yago MR; Agarwal S; Khaldoyanidi SK; Stein A
    Leuk Lymphoma; 2024 Sep; 65(9):1281-1291. PubMed ID: 38712673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
    Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
    Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
    Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF
    PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CD33 as therapeutic target in acute myeloid leukemia.
    Walter RB
    Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
    Nair-Gupta P; Diem M; Reeves D; Wang W; Schulingkamp R; Sproesser K; Mattson B; Heidrich B; Mendonça M; Joseph J; Sendecki J; Foulk B; Chu G; Fink D; Jiao Q; Wu SJ; Packman K; Elsayed Y; Attar R; Gaudet F
    Blood Adv; 2020 Mar; 4(5):906-919. PubMed ID: 32150609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.